Feline interleukin-12 as immunostimulant
OwnerHans Lutz, Christian Leutenegger +3inventors
InventorsHans Lutz, Christian Leutenegger, Nils Pedersen, Matthias Schroff, Burghardt Wittig
Life of this patent
Estimating the term…
Abstract
The use of feline interleukin-12 (IL-12) is described as an adjuvant (or immunostimulant) and in the vaccination and therapy of infectious diseases in Felidae. In addition, a procedure is disclosed which makes it possible to express the two subunits of IL-12 in the requisite mass ratio.
Claims20
A method of treatment or prophylaxis of a TH-1 deficiency-related disease or tumor in a carnivore, comprising administering to the carnivore an immunostimulant composition comprising at least one therapeutic agent selected from the group consisting of (a) feline interleukin 12, (b) polypeptides homologous to feline interleukin 12 having corresponding therapeutic effect on said disease or tumor, and nucleic acid precursors of (a) and (b).
A method of making a therapeutic composition for treatment or prophylaxis of a disease or tumor associated with TH-1 deficiency, comprising recombinantly expressing, in eukaryotic or prokaryotic cells, polypeptide comprising polypeptide chains of subunits p35 and p40 of feline interleukin 12 from nucleic acid encoding same;
- extracting said polypeptide;
- and formulating said polypeptide in said therapeutic composition, wherein subunits p35 and p40 are in equimolar concentration with respect to one another.
Dependencies are inferred from the claim text.